Grassley questions FDA's 'Safety First'

Share this article:
Sen. Charles Grassley (R-IA) says he is concerned that the FDA's Safety First initiative is merely cosmetic and will not make fundamental changes he says are needed to improve FDA's oversight of approved drugs. In a letter to FDA commissioner Andrew von Eschenbach, Grassley asked that his Finance Committee staff be briefed on the initiative. 

In addition to obtaining more details of Safety First and implementation timeframes, Grassley asked for an explanation of the agency's decision to maintain what appears to be the status quo by having the Office of Surveillance and Epidemiology (OSE) play a consulting role to the Office of New Drugs (OND) on post-marketing safety matters.

When Safety First was announced in February, FDA drugs center director Janet Woodcock said the effort would strengthen and modernize FDA's post-market drug oversight.

Grassley said his investigations into how the FDA handles post-market surveillance of drugs, biologics, medical devices, and veterinary medicines “have shown repeatedly that serious adverse events that emerge after a drug is on the market do not necessarily get prompt attention from OND. Further, safety concerns raised by OSE were sometimes ignored by OND, which is responsible for determining what, if any, regulatory actions will be taken to address a post-marketing drug safety issue.”
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete October 2014 Digital Edition

Read the complete October 2014 Digital Edition

Click the above link to access the complete Digital Edition of the October 2014 issue of MM&M, with all text, charts and pictures.

Predicting your pink slip

Predicting your pink slip

Any time a firm needs to save money, high-salaried executives are targets

Private View: New ways to engage with customers

Private View: New ways to engage with customers

These healthcare social media campaigns successfully use emotion, altruism and the human desire to "brand" oneself to get customers engaged.